Intech Biopharm Corporation (TPEX:6461)

Market Cap	3.64B
Revenue (ttm)	34.07M
Net Income (ttm)	-361.71M
Shares Out	137.94M
EPS (ttm)	-2.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,285
Average Volume	76,547
Open	26.00
Previous Close	25.75
Day's Range	25.70 - 26.05
52-Week Range	23.60 - 34.60
Beta	0.36
RSI	55.24
Earnings Date	Mar 13, 2025

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 82
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2023, Intech Biopharm's revenue was 25.85 million, an increase of 9.30% compared to the previous year's 23.65 million. Losses were -337.99 million, 3.08% more than in 2022.